The US Bankruptcy Court approved the revised plan of liquidation of Infinity Pharmaceuticals, Inc. on March 7, 2024. The debtor has filed its revised plan in the Court on March 6, 2024. As per the plan, administrative claims of $0.41 million, professional fee claims, priority tax claims of $0, statutory fees, secured tax claims of $0, other secured claims of $0 and other priority claims of $0.8 shall be paid in full in cash.

other secured claims of $0.80 million, and other priority claims of $0.80 million shall be paid in full in cash. General unsecured claims of $6.68 million shall recover 37% and receive its pro rata share of the beneficial trust interests. Subordinated claims shall be cancelled without any distribution on account of such claims. Interests will receive no distribution under the plan.

The plan shall be funded from available cash and vesting of assets.